Severe Dual Fungal Infection After Bispecific Antibody Therapy: A Case of Invasive Aspergillosis and Mucormycosis in Immunocompromised Patient

SAKALIHASAN, Sarah; LIFRANGE, Fréderic; CZAJKOWSKI, Mathieu; GONCETTE, Véronique; Duysinx, Bernard; Lovinfosse, Pierre; Can, Damla; Schils, Raphael; Hayette, Marie-Pierre; De Voeght, Adrien

doi:10.1016/j.idcr.2024.e02140

Article (Scientific journals)

Severe Dual Fungal Infection After Bispecific Antibody Therapy: A Case of Invasive Aspergillosis and Mucormycosis in Immunocompromised Patient

SAKALIHASAN, Sarah; LIFRANGE, Fréderic; CZAJKOWSKI, Mathieu et al.

2024 • In IDCases, p. 02140

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/327320

DOI
10.1016/j.idcr.2024.e02140

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S2214250924002166-main.pdf

Author postprint (865.14 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T cell which are immune-mediated. Nevertheless, infectious complication remains a major concerns with related mortality. Fungal infection are rarely reported in clinical trial but remains a major concern. We report a case of a co-infection of Aspergillus and Mucorales in a patient with diffuse large B-cell lymphoma (DLBCL) following treatment with the bispecific antibody epcoritamab. The patient developed severe cytokine release syndrome (CRS) and subsequent fungal infections, which were challenging to diagnose and treat due to the complexities of managing immunocompromised patients and co-infection. Advanced diagnostics, including PET-CT, and a combination of antifungal therapies were crucial in achieving remission. The case underscores the need for early diagnosis, multidisciplinary management, and innovative treatment strategies in similar high-risk patients.

Disciplines :

Hematology
Immunology & infectious disease

Author, co-author :

SAKALIHASAN, Sarah ; Centre Hospitalier Universitaire de Liège - CHU > > Frais communs médecine - Pool assistants

LIFRANGE, Fréderic ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques

CZAJKOWSKI, Mathieu ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'ORL, d'audiophonologie et de chir. cervico-faciale

GONCETTE, Véronique ; Centre Hospitalier Universitaire de Liège - CHU > > Service officine et gaz médicaux

Duysinx, Bernard ; Université de Liège - ULiège > Département des sciences cliniques

Lovinfosse, Pierre ; Université de Liège - ULiège > GIGA > GIGA Platforms - In Vivo Imaging - Nuclear Medicine Division

Can, Damla ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic

Schils, Raphael ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Maladies infectieuses et médecine interne générale

Hayette, Marie-Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Bactériologie, mycologie, parasitologie, virologie et microbiologie

De Voeght, Adrien ; Université de Liège - ULiège > GIGA

Language :

English

Title :

Severe Dual Fungal Infection After Bispecific Antibody Therapy: A Case of Invasive Aspergillosis and Mucormycosis in Immunocompromised Patient

Publication date :

December 2024

Journal title :

IDCases

eISSN :

2214-2509

Publisher :

Elsevier BV

Pages :

e02140

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S2214250924002166?httpAccept=text/xml

Funders :

Gilead Sciences

Available on ORBi :

since 23 January 2025

Statistics

Number of views

7 (3 by ULiège)

Number of downloads

3 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Westin, J.R., Oluwole, O.O., Kersten, M.J., Miklos, D.B., Perales, M.A., Ghobadi, A., et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 389:2 (2023), 148–157.
Jeong, S.J., Lee, J.U., Song, Y.G., Lee, K.H., Lee, M.J., Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. Mycoses 58:12 (2015), 746–752.
Chamilos, G., Lewis, R.E., Kontoyiannis, D.P., Delaying Amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47:4 (2008), 503–509.
Muthu, V., Agarwal, R., Dhooria, S., Sehgal, I.S., Prasad, K.T., Aggarwal, A.N., et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect 27:4 (2021), 538–549.
Cornely, O.A., Alastruey-Izquierdo, A., Arenz, D., Chen, S.C.A., Dannaoui, E., Hochhegger, B., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 19:12 (2019), e405–e421.
Tarrand, J.J., Lichterfeld, M., Warraich, I., Luna, M., Han, X.Y., May, G.S., et al. Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 119:6 (2003), 854–858.
Kung, V.L., Chernock, R.D., Burnham, C.A.D., Diagnostic accuracy of fungal identification in histopathology and cytopathology specimens. Eur J Clin Microbiol Infect Dis 37:1 (2018), 157–165.
Aerts, R., Bevers, S., Beuselinck, K., Schauwvlieghe, A., Lagrou, K., Maertens, J., Blood Mucorales PCR to track down aspergillus and mucorales co-infections in at-risk hematology patients: a case-control study. Front Cell Infect Microbiol, 12, 2022, 1080921.
Lass-Flörl, C., Mutschlechner, W., Aigner, M., Grif, K., Marth, C., Girschikofsky, M., et al. Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. J Clin Microbiol 51:3 (2013), 863–868.
Gouzien, L., Che, D., Cassaing, S., Lortholary, O., Letscher-Bru, V., Paccoud, O., et al. Epidemiology and prognostic factors of mucormycosis in France (2012–2022): a cross-sectional study nested in a prospective surveillance programme. Lancet Reg Health - Eur, 45, 2024, 101010.
Lanternier, F., Poiree, S., Elie, C., Garcia-Hermoso, D., Bakouboula, P., Sitbon, K., et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 70:11 (2015), 3116–3123.
Ibrahim, A.S., Gebremariam, T., Fu, Y., Edwards, J.E., Spellberg, B., Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 52:4 (2008), 1556–1558.
Pagano, L., Cornely, O.A., Busca, A., Caira, M., Cesaro, S., Gasbarrino, C., et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 98:10 (2013), e127–e130.
Cheok, K.P.L., Farrow, A., Springell, D., O'Reilly, M., Morley, S., Stone, N., et al. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US food and drug administration adverse events reporting system analysis and a review of the literature. Lancet Infect Dis 24:4 (2024), e256–e265.
Ito, K., Inhaled antifungal therapy: benefits, challenges, and clinical applications. Expert Opin Drug Deliv 19:7 (2022), 755–769.
Hilberg, O., Andersen, C.U., Henning, O., Lundby, T., Mortensen, J., Bendstrup, E., Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis: Fig. 1–. Eur Respir J 40:1 (2012), 271–273.
Muthu, V., Sehgal, I.S., Agarwal, R., Aerosolized antifungals for the treatment of pulmonary fungal diseases. Curr Fungal Infect Rep 18:2 (2024), 154–162.
Valentini, C.G., Candoni, A., Fianchi, L., Posteraro, B., Simeone, E., Costa, F., et al. Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies: zygomycoses in haematological malignancies. Mycoses 53:1 (2010), 89–92.
Alqarihi, A., Kontoyiannis, D.P., Ibrahim, A.S., Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol, 13, 2023, 1254919.
West, K.A., Gea-Banacloche, J., Stroncek, D., Kadri, S.S., Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol 177:3 (2017), 357–374.
Little, J.S., Kampouri, E., Friedman, D.Z., McCarty, T., Thompson, G.R., Kontoyiannis, D.P., et al. The burden of invasive fungal disease following chimeric antigen receptor T-revention. Open Forum Infect Dis, 11(6), 2024, ofae133.
Melica, G., Luna De Abia, A., Shah, G.L., Devlin, S., Corona, M., Fein, J., et al. Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T ohort. Transpl Cell Ther, 2024 S2666636724007279.
Little, J.S., Aleissa, M.M., Beluch, K., Gonzalez-Bocco, I.H., Marty, F.M., Manne-Goehler, J., et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv 6:16 (2022), 4821–4830.
Reynolds, G.K., Maclean, M., Cliff, E.R.S., Teh, B.W., Thursky, K.A., Slavin, M.A., et al. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv 8:13 (2024), 3555–3559.
Reynolds, G., Cliff, E.R.S., Mohyuddin, G.R., Popat, R., Midha, S., Liet Hing, M.N., et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv 7:19 (2023), 5898–5903.
Alexander, B.D., Lamoth, F., Heussel, C.P., Prokop, C.S., Desai, S.R., Morrissey, C.O., et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC. Clin Infect Dis 72:ement_2 (2021), S79–S88.
Douglas, A.P., Thursky, K.A., Worth, L.J., Drummond, E., Hogg, A., Hicks, R.J., et al. FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging. Eur J Nucl Med Mol Imaging 46:1 (2019), 166–173.
Ankrah, A.O., Span, L.F.R., Klein, H.C., De Jong, P.A., Dierckx, R.A.J.O., Kwee, T.C., et al. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. Eur J Nucl Med Mol Imaging 46:1 (2019), 174–183.